Royalty Pharma plc
Company Stats
- Market Cap
- $33.6B
- as of Sep 30, 2026
- Shares Outstanding
- 575.0M
- Free Float
- 69.9%
Income Statement
- Revenue
- $2.4B
- Operating Income
- $1.6B
- Net Income
- $770.9M
- EBITDA
- $1.6B
- Revenue Growth, 3Y
- 2.1%
Balance Sheet
- Cash & Equivalents
- $618.7M
Returns & Capital
- Share Repurchases
- $1.2B
- Buyback Yield, 3Y Avg
- 1.8%
- SBC, 3Y Avg
- $98.2M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $2.4B | — | — |
| FY2024 | $2.3B | — | — |
| FY2023 | $2.4B | — | — |
| FY2022 | $2.2B | — | — |
| FY2021 | $2.3B | — | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 14, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges